A Study to Evaluate the Efficacy and Safety of CBL-514 in Participants With EFP; Cellulite (Stage 1)

NCT05632926 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

12

Enrollment

INDUSTRY

Sponsor class

Conditions

Cellulite

Interventions

DRUG: 40 mg CBL-514
DRUG: 60 mg CBL-514
DRUG: 80 mg CBL-514

Sponsor

Caliway Biopharmaceuticals Co., Ltd.